Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is nothing to regret, zzaatt.
I chose the timing of my joining the board and the same goes for my leaving the iHub environment. It is the right thing to do.
When I leave, I leave for good (no looking back or looking for "gems in the muck").
This really is my last communication.
Thank you.
HappyBee
As indicated earlier, I am leaving the board for my own reasons.
I will keep my good bye short and I just want to say thank you to my investment friends for sharing information and constructive views. Thank you particularly to Allo for the steady supply of links.
It has been very helpful and much appreciated.
I will remain invested in Pluristem and follow its progress.
Good luck!
HappyBee
Hi Straightshot,
"The folks have shown outstanding success in manufacturing but only so-so results in trials.."
I did recall you being more positive regarding Pluristem's trial results and I checked before writing this ("great news", "good news"). I don't mean to criticise you, but I am confused as to what you are trying to say.
HappyBee
Hi zzatt and Allo,
Like both of you I thought that a partnership between Pluristem and Lonza seemed a distinct possibility. Allo, I do not recall you ever stating that your hypothesis was anything other than that and the fact that a different (and more powerful) company has entered a partnership with Pluristem is both surprising and unexpected (as far as I am concerned). I think the latest developments are seriously impressive and very reassuring and I agree with you zzaatt that hopefully this may result in a "more expeditious move toward patient benefit and clinical availability".
A nice start to the week, especially since I was convinced that there may not be any substantial Pluristem news until after the summer.
HappyBee
Hi Saud,
I am wondering whether Thermo Fisher may form part of the RESTORE consortium.
Please see below quote from the link I posted earlier.
"We are fortunate to have assembled a determined and distinguished team to reach that ultimate goal", explains Professor Volk. He adds, “RESTORE is currently integrating additional stakeholders and refining its concept to strengthen the proposal further”. "
It is just a thought.
HappyBee
"Restore Health - Therapies that cure"
Please find a link below discussing the RESTORE initiative (Pluristem are part of it).
Very interesting!
https://www.healthcapital.de/en/news/article/restore-health-therapies-that-cure/
HappyBee
PS Hi zzaatt, your recent observations about Pluristem's prospects in response to a previous post of mine seem spot on!
Happy 4th of July to everyone.
Best wishes from Europe,
HappyBee
You are welcome, zzaatt.
Maybe his professional self-preservation instinct has been kicking in.
HB
Hi zzaatt,
This name certainly rings an (alarm) bell for me as well.
My personal opinion is that a high level of arrogance paired with a lack of empathy often seem to go hand in hand with high office.
You may have already seen the link below outlining Dr Padzur's current views.
https://blogs.fda.gov/fdavoice/index.php/2017/06/in-cancer-treatment-theres-more-than-one-way-to-measure-patient-benefit/
HappyBee
"Don't let yesterday use up too much of today."
Will Rogers ("investment expert")
Hi voova,
there is no need to apologise at all!
HappyBee
Hi Saud,
many thanks for this very interesting statistic. It bodes well.
HB
Hi voova,
Thank you for the link. I think that Allo has previously posted a link as well, but it is very good to be once again reminded of Pluristem's recent achievements in such detail. It is an excellent article which leads me to this quote I like from one of zzaatt's previous posts (hi zzaatt), please see below.
"as long as you believe that the underlying science works, the daily fluctuations
of the pps is irrelevant."
I often find this board very educational and after having had a further look at Will Rogers I would like to share this quote of his I came across. Wise words for the investor :).
"When ignorance gets started it knows no bounds".
HappyBee
PS I also agree with Saud's view (hi Saud) that Pluristem have not misled anyone regarding the timeline when their products may hit the market.
Thank you for your reply EK. We may have to agree to disagree on your view of the company's progress and your averaging down "rationale". HB
Absolutely, zzaatt, I agree 100%. HB
Questions for EK.
EK, when you bought your shares 10 years ago, was this your only purchase? Have you never attempted to average down?
I have bought Pluristem shares at various price points because I wanted to own more shares in the company. Sometimes it meant that I averaged "up" and other times I averaged down.
I cannot see anything negative in averaging down.
HappyBee
Hi zzaatt,
Your quote below reflects pretty much what I have been thinking.
"The only comment I
have is that the ten year waiting period for finding out if your
investment will have a return is actually the ten years that just passed."
I can only speak for myself as a long term investor, but when I buy shares I do not buy them in the hope of a quick profit. I have been invested in this company for less than two years and so far I am very happy with my choice of investment. Even if I had bought shares 10 years ago I would be encouraged to hold my shares as a consequence of the steady progress Pluristem have been making. There is no denying that considerable progress has been made, it is all on public record. I share your view that we will not have to wait another ten years to see a return on our investment. I think it will be a fraction of the 10 year time line.
HappyBee
Good evening Saud,
I would like to echo your sentiments. Thank you Allo!
HappyBee
PS Hi zzaatt, you are welcome. It is very good to see you posting again.
Indeed I am, Saud.
Welcome back to the board, zzaatt! You have lost none of your posting mojo!
Best wishes,
HappyBee
Right on, Robbie! Always trust your own judgment.
Welcome to the board!
HappyBee
PS "Indicators" are just that, "indicators".
:) :) :)
Thank you, Allo!
HB
PS Hi Thunderforce, well said.
Thank you, Kiki.
I completely agree with your view "Do feel Pluristem is like a hidden gem" and one that seems to be hiding in plain sight. There is so much potential and hopefully the sky won't be the limit.
HappyBee
PS I do appreciate your positive outlook.
Hi PLX-11, Kiki and Allo,
Allo, thank you for posting the article, it was a great read.
PLX-11, a former Amgen employee, Dr Roger Jeffs, recently joined Pluristem's strategic advisory board. The quotes below are from a news release following his appointment.
"Dr. Jeffs commented, “Pluristem’s placental cell therapies, currently being evaluated in multiple advanced clinical trials, could significantly advance regenerative medicine and make a change in the way patients are treated today, by delivering a safe and effective off-the-shelf cell therapy. The Company’s manufacturing assets are a key to its commercialization capabilities. I look forward to working with Pluristem’s management team to move the clinical programs forward towards marketing.”
“Dr. Jeffs brings tremendous expertise and vision to Pluristem, from business aspects, to clinical development, marketing approval and commercialization. His work in developing Neupogen is directly relevant to our PLX-R18 clinical program in the treatment of bone marrow deficiencies,” stated Pluristem Chairman and Co-CEO Zami Aberman. “Pluristem is now forming a senior strategic advisory board in t preparing the Company toward expansion and commercialization. We are honored and pleased that Dr. Jeffs is joining us at this important time.”
https://globenewswire.com/news-release/2018/03/26/1452756/0/en/Roger-Jeffs-Former-Co-CEO-of-United-Therapeutics-Joins-Pluristem-s-Strategic-Advisory-Board.html
I cannot make any sense of what the share price is doing, but naturally as a shareholder I would like to see it at a higher level. However, thinking long-term, my attention tends to be drawn to the progress of Pluristem's clinical programs. This (to me) is what counts and holds my interest. I find it highly encouraging that an industry "heavyweight" like Dr Jeff with such wide ranging experience and an interesting track record (i.e. Neupogen) in the sector sees the potential in Pluristem's therapies and has given his endorsement by being actively associated with the company.
Kiki, I would not be surprised looking further ahead, if as you say "PLX-R18 will become the go-to treatment for people whose immune system, heart and bone marrow are compromised by chemotherapy and radiation treatment."
HappyBee
Hi Gary,
Thank you for your recent posts, they were interesting to read.
The link below to the Homeland Securities website may be of interest to you (and others like Allo, Saud, zzaatt).
https://www.dhs.gov/unsolicited-proposals
I hope you have a nice holiday.
HappyBee
Hi Allo,
Many thanks for the information you have posted today (I think the old was a perfect companion piece for the new).
You say "Ignorance is Bliss". Quite!
With respect to a previous post (not by you), see relevant quote below, I would like to say that if Pluristem were required to test any of their therapies in one hundred and eleven trials, we may (just a guess!) have to live beyond age 150. :)
"Then of course it's the lenght [sic] of time it takes to get Phase111 completed and proven. 1yr-2 yrs???"
HappyBee
PS I see Athersys are down by almost 10% today.
PPS I am not a paying member therefore my opportunities to respond to private messages are limited.
Good morning,
Links that don't work, claims of incorrect translation without any evidence...
Holding Pluristem shares for 10 years and being disgruntled, sounds familiar.
How droll! EOM
Hi Allo,
Thank you for posting this interesting article and we may be thinking along similar lines.
When you look at the two quotes below, the first from your article and the second from last week's news release, it strikes me that once again it appears that patients in the U.S. fared particularly well. Please correct me, if I'm wrong.
"Whatever this means, it does point to the fact that Europe is very interested in seeing why the initial Phase I trial results for PLX-PAD in CLI were so successful, especially in the U.S. trial."
"Key primary efficacy endpoint, improvement in MWD as compared to placebo, in analysis by country, showed best results with statistically significant improvement (effect size= 51.1%, p=0.015) in U.S patients (n=73) treated with 2 administrations of 300 million PLX-PAD cells."
HappyBee
Hi Saud,
I have already responded to your post once in a more light-hearted way, but I thought you may be interested in an article titled "Living to 100 Growing Societal Impact And Challenges-SOA". It is a PDF and therefore I cannot post a direct link. If you put the text below in the Google search bar the article will appear near the top of the results. There is so much to think about.
https://www.soa.org/library/newsletters/the.../act-2011-vol8-iss4-rappaport.
HappyBee
Hi Saud,
these are a very good questions. We would certainly need much more money to live that long (in style) and what would we all look like aged 149 years? :)
HappyBee
PS Hi Midas, thank your for the information, it is much appreciated. Approval within a year would be excellent news. It is also interesting (but not surprising) how the medical community appears to view the trial results differently to the market. I side with the doctors on this. HB
Hi Allo,
Many thanks for all the helpful information and links you have posted over the last few days (thank you to Spidey and voova as well for the scientific input). Like you I do hope that Pluristem will become a global leader in cell therapies in years to come. They seem to have so much potential as a company.
Please find below a link to an article discussing the Westchester Biotech Project event on the 12th of June. It contains a reference to Karine Kleinhaus. Do you know who the surprise guest was?
https://eu.lohud.com/story/opinion/perspective/2018/06/14/biotech-community-future/697785002/
Best wishes,
HappyBee
Thank you for clarifying, voova. That is very helpful.
HappyBee
Thank you for providing a link and translation from Google Translate for the article, PLX-11.
I don't speak Hebrew, but something must have got lost in translation. The translated version of the article appears to contradict the information from the news release.
Article.
"Pluristem was unable (Able?) to show statistical significance at the primary trial target, which was an improvement in the maximal walking distance of patients who received two injections of 300 million PLX-PAD cells compared to patients who received placebo after 52 weeks."
News Release.
"Patients treated with 2 administrations of 300 million PLX-PAD cells showed statistically significant improvement (p=0.0008) in MWD as compared to baseline at 52 weeks."
The reference to endometriosis surely must be wrong.
"The cost of treatment for the American health system in severe endometriosis is estimated at $ 50,000 per patient per year and the total cost of $ 10 billion is the same as in Europe."
HappyBee
PS I do agree with your investment strategy (your earlier post). Regardless of the share price the recent clinical data is a ray of sunshine.
Correction.
Contrary to what I stated yesterday there is a lot of interesting information (in English) available on the website of the Frankfurt stock exchange.
When you click on the link below and scroll right down you will find a side bar with the header "Trending Themes" (next to a share price graph).
HappyBee
PS Hi Allo, I hope you feel more cheerful today.
Thank you for this information senderos. I wasn't sure either.
HappyBee
Hi Saud,
Many thanks for posting the link. I am very pleased about this news and hopefully it will give Pluristem further publicity.
I was only thinking this morning how much under the radar this company is. This week's positive news seem to have hardly registered in the financial press in Germany. Pluristem are listed on the website of the Frankfurt stock exchange. I can get information about the share price, but there are no news reported at all (not even in English). There is no description of the company either even though there is a facility to put this information on the website.
HappyBee
Hi PLX-11,
Thank you for the article. It provides an interesting perspective on bringing cell and gene therapies to market.
I agree that changing the status quo can take a long time. It also presents unique challenges and uncertainties. It is encouraging that both the EMA and FDA have recognised the need to adapt their processes to new therapeutic technologies. This new evolving regulatory environment seems to strongly favour therapies like Pluristem's and I think they are in a good place. The example (withdrawal) of Glybera is an extraordinary and extreme one, but I cannot envisage a situation like that for Pluristem.
HappyBee
PS Thank you, Allo, for confirming my thoughts regarding conditional marketing approval (I'm glad that my cognitive function seems to have been somewhat restored :)). That really would be "Beyond HUGE! "
Thank you, Allo. It seems the news are getting better and better (regardless of the share price). If I understand the content of the link below correctly, positive interim results for the CLI trial may set the scene for early marketing approval in Europe. Exciting times.
"PLX-PAD cells have been selected by the European Medicines Agency (EMA) to be developed for CLI via the Adaptive Pathways pilot project. Under this regulatory pathway, the multinational Phase III trial may potentially lead to early marketing approval of PLX-PAD for CLI in Europe, based on interim efficacy data from the first 125 patients that have completed a follow-up of 12 months."
https://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=754157&
Can I hear a "MOLTO bellissimo" in the distance? I certainly hope so.
HappyBee
Agreed, Allo. Well done Pluristem! This is very good news for everyone who has kept faith with the company.
I wonder if ultimately this therapeutic (and by all accounts well-tolerated) approach could be applied to certain cardiac diseases, see quote below.
“We are highly encouraged by the results seen in the study. The option of treating peripheral artery diseases like IC and CLI through IM injections of PLX-PAD cells is promising, and an important outcome, demonstrating the potential ability to implement regenerative medicine advanced technologies in cardiovascular diseases. We look forward to the CLI pivotal study results that may demonstrate the ability of Pluristem’s cell therapy to improve patient outcomes and create economic benefits for the healthcare systems,” stated Dr. Manesh Patel, Chief of the Division of Cardiology at Duke University Health System, and the lead principle investigator (PI) for the U.S. Phase II IC study."
HappyBee
Definitely, maybe. :)